Multicentric Pilot Phase II Study for use of Fludarabine plus Cyclophosphamide Followed by 90 Y-Ibritumomab Tiuxetan Zevalin in the Treatment of non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine
- Conditions
- Treatment patients with non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine and Ciclofosfamide
- Registration Number
- EUCTR2005-000699-41-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method